Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||DCC-3116 + Sotorasib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|DCC-3116||DCC 3116|DCC3116||DCC316 selectively inhibits ULK1/2, leading to decreased phosphorylation of its substrate ATG13 and inhibition of autophagosome formation, and may lead to inhibition of tumor cell growth (Mol Cancer Ther 2019;18(12 Suppl):Abstract nr B129).|
|Sotorasib||Lumakras||AMG 510|AMG510|AMG-510||KRAS G12C inhibitor 29||Lumakras (sotorasib) is small molecule inhibitor that selectively targets KRAS G12C and inhibits downstream signaling, which may lead to growth inhibition of tumors harboring KRAS G12C (PMID: 31666701). Lumakras (sotorasib) is FDA approved for use in patients with locally advanced or metastatic non-small cell lung cancer harboring KRAS G12C who have received one or more prior therapy (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04892017||Phase Ib/II||DCC-3116 + Sotorasib Binimetinib + DCC-3116 DCC-3116 DCC-3116 + Trametinib||A Phase 1/2 Study of DCC-3116 in Patients With MAPK Pathway Mutant Solid Tumors||Recruiting||USA||0|